speaker-photo

Aaron Mann

Chief Executive Officer at Windgap Medical

I am privileged to be the CEO of Windgap Medical, a privately-held drug delivery company
focused on solutions which simplify, automate, and accelerate the delivery of difficult-to-mix
drugs. Our solutions free patients, families, and complex therapies from the limitations of
current delivery systems. In partnership with leading biopharmaceutical companies, we are
working to bring these solutions to patients.
Previously, I was CEO at Kindeva Drug Delivery, a leading global CDMO to
biopharmaceutical companies, with over 1000 talented colleagues, which was spun out of 3M
in 2020, backed by Altaris Capital Partners. Kindeva's capabilities span inhalation,
transdermal and microneedles, from pre-clinical work, through regulatory processes and
approval, into commercial scale and supply with sites in the US and the UK. Through
COVID and over the course of two years we fully separated the business from 3M and
established a clean, global, modern set of systems and processes.
At 3M, I led the Drug Delivery Systems business, a global leader in the contract formulation,
development, and manufacturing of delivery systems for complex molecules. I also held
responsibility for strategy and business development for the Health Care Business Group,
completing ~$8B of transactions. Key accomplishments include the acquisitions of Acelity
(wound care) and mModal (health IT).
Earlier, I ran corporate development, strategy, and marketing at Phillips-Medisize, a Molex
company. Phillips-Medisize is a global contract designer and manufacturer of drug delivery
and medical device products Golden Gate Capital sold Phillips-Medisize to Molex and Koch
Industries in October 2016. I've also led Operations at Remedi Senior Care, a Centerbridge
Partners portfolio company. Remedi, an institutional pharmacy, was built around a
proprietary high-speed automated dispensing system, serving over 30,000 long-term care
residents from 6 pharmacies 24x7x365.
I began my career at Bain & Company, spending significant time across four continents and
multiple industries and wide range of capabilities. I graduated from the Harvard Business
School and Carleton College.

Aaron Mann
Chief Executive Officer
Windgap Medical

Aaron Mann, Chief Executive Officer at Windgap Medical

I am privileged to be the CEO of Windgap Medical, a privately-held drug delivery company focused on solutions which simplify, automate, and accelerate the delivery of difficult-to-mix drugs. Our solutions free patients, families, and complex therapies from the limitations of current delivery systems. In partnership with leading biopharmaceutical companies, we are working to bring these solutions to patients.

Previously, I was CEO at Kindeva Drug Delivery, a leading global CDMO to biopharmaceutical companies, with over 1000 talented colleagues, which was spun out of 3M in 2020, backed by Altaris Capital Partners. Kindeva’s capabilities span inhalation, transdermal and microneedles, from pre-clinical work, through regulatory processes and approval, into commercial scale and supply with sites in the US and the UK. Through COVID and over the course of two years we fully separated the business from 3M and established a clean, global, modern set of systems and processes.

At 3M, I led the Drug Delivery Systems business, a global leader in the contract formulation, development, and manufacturing of delivery systems for complex molecules. I also held responsibility for strategy and business development for the Health Care Business Group, completing ~$8B of transactions. Key accomplishments include the acquisitions of Acelity (wound care) and mModal (health IT). Earlier, I ran corporate development, strategy, and marketing at Phillips-Medisize, a Molex company. Phillips-Medisize is a global contract designer and manufacturer of drug delivery and medical device products Golden Gate Capital sold Phillips-Medisize to Molex and Koch Industries in October 2016.

I’ve also led Operations at Remedi Senior Care, a Centerbridge Partners portfolio company. Remedi, an institutional pharmacy, was built around a proprietary high-speed automated dispensing system, serving over 30,000 long-term care residents from 6 pharmacies 24x7x365. I began my career at Bain & Company, spending significant time across four continents and multiple industries and wide range of capabilities. I graduated from the Harvard Business School and Carleton College.